An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT01187381 · clinicaltrials.gov ↗

TERMINATED

Status

250

Enrollment

INDUSTRY

Sponsor class

Stopped Study was prematurely terminated because of missing data collection.

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab

Sponsor

Hoffmann-La Roche